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Abstract
Background and Objectives Subcutaneous immunoglob-
ulin (SCIG) therapy is becoming increasingly popular as
self-administration is possible because intravenous access
is unnecessary, and there is a lower frequency of systemic
adverse events. The aim of this study was to evaluate the
shifting from intravenous immunoglobulins (IVIGs)
replacement therapy to SCIG in patients with primary
immunodeficiency (PID) in a routine real-life situation.
Methods In a multicenter prospective observational
study, we enrolled 50 patients suffering from PID who
were monitored for 24 months; 44 patients switched from
IVIG and six from different SCIG preparations. The study
preparation (human IgG 16 %, Vivaglobin, CSL Behring
GmbH, Germany) was subcutaneously infused weekly
(maximum volume 15 mL/site; maximum infusion rate
22 mL/h). The study endpoints were: annual rate of severe
bacterial infections (SBIs), local adverse reactions, quality
of life, days off school/work, and days of hospitalization.
Results Thirty-three of 39 (84.6 %) patients who com-
pleted the study experienced an infection or signs thereof.
Only five SBIs were observed, corresponding to an annual
rate of 0.056 episodes per patient in 44 subjects [intention-
to-treat (ITT) population]. A significant decrease in both
days of hospitalization (1.93 ± 4.08 vs. 0.64 ± 2.94) and
days off school/work (15.27 ± 23.17 vs. 2.26 ± 4.45) was
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recorded at 24 months. Local reactions were observed in
14/50 (28 %) patients, mainly consisting of skin manifes-
tations at the injection site. Only three (6.8 %) patients
discontinued due to infusion site reactions. In patients
shifting from IVIG to SCIG, the total mean score of Life
Quality Index (LQI) improved from 76.9 ± 16.8 to
90.7 ± 11.6 (P \ 0.01) at 6 months; there was an im-
provement also in the overall patients’ evaluation.
Conclusions A total of 93.2 % patients tolerated the new
route of administration and reported a significant im-
provement in their LQI. Our results from a routine clinical
practice in a real-life population are consistent with those
of phase III clinical studies.
Key Points
SCIG therapy is effective and well tolerated in
real-life situations.
SCIG therapy leads to a less interference with private
life and work.
SCIG therapy increases the treatment satisfaction
referred by PID patients.
1 Introduction
Primary immunodeficiency (PID) disorders that predispose
patients to recurrent respiratory, skin, and gastrointestinal
infections, require immunoglobulin (Ig) replacement ther-
apy. Ig replacement therapy is beneficial although the op-
timal immunoglobulin G (IgG) trough level to be
maintained over time in order to minimize risks of infec-
tions has not yet been established [1]. The most common
method of administration of Ig is via the intravenous
(IVIG) route, although today there are different options, for
example the subcutaneous route. Subcutaneous Ig (SCIG)
replacement offers many advantages, such as the mainte-
nance of stable serum IgG levels in comparison to IVIG,
hospital-free setting, improvement of patients’ quality of
life (QoL), better tolerability, and low incidence of side
effects [2]. Dosing of SCIG in PID patients should be based
on their current dose of IVIG as well as their serum trough
levels. The weekly subcutaneous dose should be calculated
by dividing by four the current monthly intravenous dose
corresponding to the new treatment interval [3, 4].
Our prospective, observational, 24-month, multicenter
study was designed to verify whether the tolerability profile
of the SCIG administration shown during phase III pivotal
trials [3, 5] carried out on a selected population, was
confirmed during the subcutaneous administration of
Vivaglobin (CSL Behring GmbH, Germany) in PID pa-
tients, in a routine clinical real-life setting. Indeed, Gardulf
et al. [3] determined the annualized rate of severe infec-
tions as 0.04 episodes/patient; moreover, 28 (1 %) systemic
adverse reactions occurred, none of them severe. Local
tissue reactions declined over time, this being particularly
evident after 8–10 weeks. Ochs et al. [5] recorded two
patients (4 %) who reported one severe bacterial infection
each (pneumonia), with an annual rate of 0.04 per patient-
year. The most frequent treatment-related adverse event
was infusion-site reaction (91 % of patients), which was
predominantly mild or moderate and decreased over time.
We also collected efficacy data and the impact, if any,
on the patients’ QoL.
2 Patients and Methods
2.1 Study Design and Patients
The study described herein is a prospective, 24-month,
observational, multicenter study. Fifty patients (31 males
and 19 females) with PID according to the definitions
provided by the European Society for Immunodeficiencies
(ESID), [32 Common Variable Immunodeficiency-CVID,
10 X-linked agammaglobulinemia (XLA), 8 others], were
enrolled in 11 study sites in Italy. Inclusion of patients was
decided according to the possibility and willingness to
begin using the SCIG therapy, as assessed by the local
trialist. Table 1 shows demographic and baseline data. The
intention-to-treat (ITT) population (44 subjects) was de-
fined as subjects with baseline data, who completed at least
one follow-up. Thirty-nine patients were considered per-
protocol (i.e., subjects who completed the 24-month ob-
servation). Safety population included 50 patients. For QoL
assessment, the participants were divided into two groups
according to age: Group A (older than 14 years, n = 43),
Group B (14 years or younger, n = 7). Follow-up visits
were at 6, 12 and 24 months after study initiation. The
study was performed in accordance with the International
Conference on Harmonization, Good Clinical Practice
guidelines and the Declaration of Helsinki, and received
approval by the local Institutional Review Boards. All
patients and/or carers provided their written, informed
consent, including also the anonymous disclosure of
findings.
2.2 Subcutaneous Immunoglobulin
Subcutaneous immunoglobulin (SCIG) was given as a
weekly infusion by using a liquid pasteurized, polyvalent,
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human 16 % preparation (160 mg/mL) (Vivaglobin, CSL
Behring GmbH, Germany). The patients maintained the
total monthly dose of the previous Ig replacement therapy,
split into four weekly doses. Serum IgG trough levels were
monitored. The preparation was administered subcuta-
neously using infusion pumps in the abdomen or thigh. The
maximum volume per injection site was 15 mL and the
maximum infusion rate per site of 22 mL/h. Patients
switching to the study therapy were trained and supervised
weekly at the local hospital before starting self-infusions at
home. The carers either infused their children or supervised
the treatment. Patients already on a different SCIG treat-
ment continued with their established infusion technique.
No premedication was given.
2.3 Primary and Secondary Endpoints
2.3.1 Efficacy and Safety Assessment
The primary endpoint for efficacy was the annual rate of
severe bacterial infections (SBIs) per patient, as defined by
the FDA (Food and Drug Administration), including bac-
terial pneumonia, bacteremia/septicemia, osteomyelitis/
septic arthritis, bacterial meningitis, and visceral abscess
[6]. The diagnosis of SBIs was performed according to
standard medical procedures, such as physical examina-
tion, laboratory tests, bacterial cultures and imaging.
Secondary end-points were reported by each patient in a
specific diary, including number of days off school/work,
days of hospitalization due to infections as well as local
and systemic tolerability, which was assessed by patients
and then reviewed by the investigator during the follow-up
visits.
2.3.2 Quality of Life Assessment
The acceptability of SCIG and its impact on overall QoL
were evaluated by using standardized, validated health-
related QoL (HRQoL) questionnaires, such as the Child
Health Questionnaire–Parental Form 50 (CHQ-PF50), the
Short Form 36 (SF-36), and the Life Quality Index (LQI).
The subjects and/or carers completed these questionnaires
at baseline and at the follow-up visits (6, 12, and
24 months). The CHQ-PF50 was used for children and
young adolescents up to 14 years of age and was, for the
most part, completed by carers. The assessment evaluates
15 concepts and focuses on the physical and psychosocial
functioning and well-being of the child and his or her
family. The Short Form 36 (SF-36) was used for adults, and
we referred to 35 items divided into eight subscales: phy-
sical function (10 items), role-physical (4 items), body pain
(2 items), general health (5 items), vitality (4 items), social
function (2 items), role-emotional (3 items), and mental
health (5 items). Higher scores indicated a better HRQoL
in both questionnaires. The LQI examines the respondent’s
perceptions of the impact of the IgG treatment on daily
activities. The LQI is worded without referencing home or
clinic-based settings [7]. Patients’ perception of their
general health was also evaluated by the subjects using
a 100-mm Visual Analogue Scale (VAS) ranging from 0
(worst) to 100 (best). Data were also collected regarding
days off school/work in the 12 months prior to enrollment
and recorded during the observation period, in patient’s
diaries.
2.4 Statistical Methodology
Since the number of subjects enrolled in phase III multi-
center international trials ranged between 20–40, an
evaluable population of 30 patients was considered an
adequate sample for the present 1-year, single-country
study. For subjects for whom data were available for the
entire study period, we adopted the Friedman’s non-para-
metric test for repeated measures. Descriptive statistics was
also applied. No post-hoc analysis was performed. Statis-
tical significance was defined by P values \ 0.05. BMDP
Dynamic 2009 v.8.2. was used for calculations [8].
3 Results
The recruitment period was 12 months in each center. The
recruitment started in October 2008 and was completed in
Table 1 Demographic baseline characteristics of patients
Parameters Values
Patients enrolled, na 50
Group A (older than 14 years), n 43
Group B (up to 14 years), n 7
Age, years, mean ± SD 31.7 ± 15.7
ITT patients, n (%)b 44 (88 %)
Per protocol patients, nc 39
Primary immunodeficiency diagnosis
Common variable immunodeficiency, n (%) 32 (64 %)
X-linked agammaglobulinemia, n (%) 10 (20 %)
Others, n (%) 8 (16 %)
Previous Ig treatment
Intravenous, n (%) 44 (88 %)
Subcutaneous, n (%) 6 (12 %)
Baseline serum trough IgG levels, mg/dL, mean ± SD 635 ± 242.8
SD standard deviation, ITT intention-to-treat, Ig immunoglobulin
a Safety population
b Patients with baseline data who completed at least one follow-up
c Patients completing the 24-month observation period
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March 2011, for an overall recruitment period of about
29 months.
Patients and/or carers required four to seven training
sessions to familiarize themselves with the subcutaneous
infusion.
A total of 39 patients completed the 24-month obser-
vation period.
Trough mean serum levels of IgG antibodies increased
slightly during SCIG treatment from 635 ± 242.8 to
671.5 ± 217.5 mg/dL (ns).
3.1 Severe Bacterial Infections and Infectious
Complications
Five SBIs (all bacterial pneumonia) were observed in five
patients, corresponding to an infection rate of 0.056 per
patient/year (ITT population).
Thirty-three out of 39 (84.6 %) evaluable per protocol
patients experienced at least one infection or possible signs
or symptoms of infection during the 24-month follow-up
period. Sinusitis (52 %), bronchitis (46 %), gastrointestinal
(34 %) and urinary infections (4 %) were most frequently
reported. Days off work/school decreased significantly
during the SCIG therapy (baseline data on 41 subjects)
(Fig. 1). A small non-significant reduction was also
recorded in the number of days in hospital (1.93 ± 4.08 vs.
0.64 ± 2.94), which was lower during the use of SCIG.
3.2 Improvement in the Quality Of Life
No significant improvement during the SCIG treatment was
observed in QoL assessment at 6, 12 and 24 months in both
Group A (n = 44) and Group B (n = 5) compared to
baseline values (Fig. 2a, b). However, for both groups the
total mean LQI score improved significantly from
76.88 ± 16.76 to 90.67 ± 11.64 (P \ 0.01) at 6 months,
and the improvement was sustained over time (Fig. 3).
Indeed, the patients’ overall evaluation of Ig therapy im-
proved significantly (P \ 0.05) in the 37 subjects shifting
from IVIG to SCIG, when comparing the baseline with the
final evaluation at the end of the 24-month observation
period. Based on the 100-mm VAS scale, the subjective
assessment of the general health status associated with
SCIG therapy showed a slightly non-significant increase
compared to baseline values (65.27 ± 17.83 vs.
68.26 ± 19.78).
3.3 Safety: Local and Systemic Adverse Reactions
Local reactions and symptoms were observed in 14 (28 %)
out of the total of 50 enrolled patients, representing the
safety population. Skin manifestations (erythema, edema,
itching and pain) at the injection site were the most com-
mon findings. They were observed in 18, 20 and 14 % of
patients at 6, 12 and 24 months, respectively, thus showing
a slight tendency to decrease, which confirms previous
findings [4]. Systemic symptoms included nausea, fever
and diarrhea and their overall incidence remained stable
over time (Fig. 4). No severe systemic adverse reactions
were recorded. Three patients (7 %) discontinued SCIG
therapy due to infusion-site reactions characterized by local
pain. No remarkable changes in hematological or other
laboratory parameters were observed during the study, and
no product-related, virus-safety issues were found.
3.4 Drop Outs
Eleven out of 50 (22 %) patients discontinued the study.
Six patients withdrew at the 6-month follow-up, two pa-
tients at month 12 and three patients at month 24. Reasons
for patient discontinuation were absence from follow-ups
(n = 3, 27.3 %), change of Ig preparations (n = 4,
Fig. 1 Days off work/school in
PID patients during the
24-month observation period.
Mean (SD) values of days off
work or school for the ITT
population at 6, 12, and
24 months from the switch to
SCIG. Data obtained from both
descriptive analysis and
Friedman’s test, are reported.
Retrospective baseline data are
relating to the 12 months prior
to enrolling (n = 41). PID
primary immunodeficiency, ITT
intention-to-treat, SCIG
subcutaneous immunoglobulin
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36.3 %), no compliance (n = 1, 9.0 %) and adverse reac-
tions (n = 3, 27.3 %).
4 Discussion
PID disorders that predispose patients to recurrent infec-
tions require Ig replacement therapy. Intravenous Ig ad-
ministration has been established as a safe and efficacious
treatment in patients suffering from PID [1]. However,
subcutaneous administration of Ig provides a better treat-
ment experience for these patients by allowing home
therapy, thus avoiding hospitalization, and maintaining
stable IgG serum levels [3, 9]. In addition, for most pa-
tients, self-administration results in improved convenience,
such as fewer absences from work and school.
Overall, the results of the VISPO study showed that
Vivaglobin was effective and well tolerated in the real-
life routine population performing self-administration at
home.
It is known that patients suffering from PID may ex-
perience a high rate of four or more severe respiratory
infections/year without Ig replacement therapy. In our ex-
perience, SCIG treatment has proven to be effective as
Fig. 2 Results of HRQoL
questionnaires. The Short Form
36 (SF-36) was used for Group
A, older than 14 years (n = 44).
The Child Health
Questionnaire-Parental Form 50
(CHQ-PF50) was used for
Group B, 14 years or younger,
and answered by the carers
(n = 5). HRQoL health-related
quality of life
Fig. 3 Treatment satisfaction
assessed by Life Quality Index
scale. Data are given as self-
reported summary scores at
baseline, at 6, 12 and 24 months
(Group A, n = 44; Group B,
n = 5). Data obtained from both
descriptive analysis and
Friedman’s test, are reported. A
maximum summary score of
105 indicates the highest
possible satisfaction with the
treatment on factors such as
independence, therapy
convenience, social/work/
school activities, and health and
travel costs
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shown by a low annualized rate of SBI (0.06 SBI/patient/
year) recorded during the 24-month follow-up period. Our
data are in line with previously published results obtained
in a prospective, multicenter study [10].
In the follow-up period of our study, minor infections
such as sinusitis, bronchitis, and gastrointestinal infections
were recorded but did not result in days off work/school.
Moreover, a significant reduction in days off work/school
was observed during the SCIG treatment. This is strictly
related to the impact of the treatment on QoL. Group A
(patients older than 14 years) did not report any sig-
nificant improvement of SF-36 scores (mental and phy-
sical health) at 6, 12 and 24 months, compared to
baseline. Similarly, the smaller Group B (patients
14 years or younger) did not report any improvement of
CHQ-PF50 scales. These results appear in contrast to
those reported in other studies performed in Europe and
North America, which found significant improvement of
HRQoL in patients suffering from PID treated with SCIG
[11, 12]. However, the LQI index, which records the re-
spondent’s perceptions of the impact of SCIG-treatment
on daily activities, was better tailored to collect the po-
tential advantages of the home-based SCIG therapy and
the reduced dependency from hospital. In fact, in both
groups, the total mean LQI score significantly improved
at six months, and was maintained over time. In addition,
the increase in treatment satisfaction, referred by patients
shifting from IVIG to SCIG, reflects and confirms the
improvement of LQI induced by the subcutaneous
therapy.
However, from our study it is not possible to define
whether the improvement of LQI is primarily related to the
use of the SCIG therapy itself, the switch to home treat-
ments, or both. The LQI improvement showed that SCIG
therapy allowed greater independence, less impact on
work/school and social activities, and treatment flexibility
with less disruption of daily activities.
Since SCIG therapy could minimize the impact of
chronic diseases, such as PID, on patients’ and families’
active lives without compromising therapy, it could be
particularly suitable both for children and working people.
Other advantages of SCIG include its lower rate of ad-
verse reactions compared with IVIG [3, 8, 9].
The VISPO study confirmed that SCIG therapy is well
tolerated, with no apparent safety concerns. In fact, Viva-
globin treatment showed good tolerability with regard to
both local injection-site reactions and systemic adverse
reactions. It is important to note that in the VISPO
population, systemic symptoms included fever, nausea, and
diarrhea, but no severe systemic reaction was recorded.
However, three subjects discontinued the treatment due to
local pain caused by the subcutaneous injection, an ob-
servation which is consistent with previous international
clinical trials [3, 4]. The safety profile of SCIG emerging
from phase III trials—even if direct comparative studies
have not been performed—led health authorities to autho-
rize SCIGs for home treatment, whereas IVIGs, in most of
the countries, are authorized for hospital use only [3, 4].
The rate of withdrawal due to injection-site reactions
can be minimized by patient education on the correct
technique of administration, adherence to the infusion
schedule, as well as by informing patients that possible
local reactions should be expected. It should be emphasized
that none of our patients received premedication.
Strictly related to the SCIG home treatment is the fact
that life-threatening anaphylactic shock, has not been
recorded so far. In fact, the administration of small doses
using the subcutaneous route favored gradual absorption
and decreased the incidence of hypersensitivity immediate
reactions [3, 8]. Moreover, the safety profile of SCIG is
confirmed by the clinical observations that it can be ad-
ministered to patients with anti-IgA antibodies, and pa-
tients who are potentially at risk for anaphylactic reactions
during IVIG therapy [13]. In addition, in these patients,
Fig. 4 Treatment-related most
common adverse reactions. Skin
reactions include redness,
edema, itching and pain at the
injection site (n = 50)
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SCIG may even lead to a decrease of anti-IgA antibodies
[5].
Finally, considering the issue regarding venous access
for IVIG, the subcutaneous route of administration, is an
additional benefit particularly in young subjects. Therapy
with SCIG can minimize the use of corticosteroids and
antihistamines prior to infusions, which is an additional
benefit taking into account the life-long treatment plan.
5 Conclusion
In conclusion, the VISPO study performed in a real-life
setting, confirmed the preliminary results of phase III trials
with regard to the additional benefits of the SCIG therapy,
particularly the improved systemic tolerability that allows
self-infusion at home leading to better management of the
disease and less interference with private life and work.
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